GlobeImmune presents GI-4000 Phase 2 NSCLC data at IASLC Continue reading
GlobeImmune Announces Presentation of GI-4000 Phase 2 Data at IASLC World Conference on Lung Cancer
October 27, 2013
NEWSROOM Archives: 2013 Press Releases
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection
October 15, 2013
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) Continue reading
GlobeImmune Awarded $4 Million NIH Grant to Develop Tarmogens for the Treatment of Tuberculosis
September 04, 2013
LOUISVILLE, Colo., September 4, 2013 – GlobeImmune, Inc., announced today that it has been awarded a $4 million Research Project Grant (R01) by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to … Continue reading
GlobeImmune to Present at 12th Annual Needham Healthcare Conference
April 18, 2013
GlobeImmune, Inc., today announced that Timothy C. Rodell, M.D. will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 in New York. Continue reading
GlobeImmune Initiates Phase 2 Study of a Novel T Cell Stimulating Cancer Vaccine (GI-6207) Targeting CEA in Patients with Metastatic Medullary Thyroid Cancer
April 03, 2013
GlobeImmune, Inc., announced today the initiation of a Phase 2 clinical trial at the National Cancer Institute (NCI) to evaluate GI-6207 in subjects with medullary thyroid cancer (MTC). Continue reading
GlobeImmune Initiates Phase 1a Clinical Trial of GI-13020 in Healthy Volunteers
January 28, 2013
LOUISVILLE, Colo., Jan. 28, 2013 – GlobeImmune, Inc., today announced the initiation of a Phase 1a clinical trial to investigate the safety and immunogenicity of GI-13020 in healthy volunteers. The GI-13020 Tarmogen®, which GlobeImmune is developing in collaboration with Gilead … Continue reading